ZEO ScientifiX
Organicell, a Miami-based biotech firm, pioneers in developing exosome therapeutics and placental tissue research since 2014.
Founded
2014Organicell, a Miami-based biotech firm, pioneers in developing exosome therapeutics and placental tissue research since 2014.
Founded in 2014 and headquartered in Miami, Florida, Organicell Regenerative Medicine is a biotech company specializing in exosome therapeutics and placental tissue research. The company's core mission is to revolutionize regenerative medicine by integrating exosome technology with other synergistic therapies, aiming to become a leading healthcare technology incubator for biologic medicine. Organicell's flagship product, Patient Pure X™ (PPX™), is a concentrated autologous exosome product derived from a patient's own blood, designed to reduce inflammation and promote tissue healing.
Notable figures associated with Organicell include its team of pioneering scientists and medical professionals dedicated to advancing exosome research. The company has attracted significant investment from stakeholders interested in the future of regenerative medicine. Key achievements include the development and successful deployment of PPX™, which has shown promising results in decreasing inflammation and aiding tissue repair. Overall, Organicell has made a substantial impact on the biotech industry by pushing the boundaries of biologic medicine and offering innovative therapeutic solutions.
Companies similar to ZEO ScientifiX include Rion, Xostem, Celularity and Exovita Biosciences.
ZEO ScientifiX was founded in 2014.
ZEO ScientifiX's headquarters is located in Miami, FL, US.
ZEO ScientifiX's most recent funding round was for $4M (USD) in July 2022.
As of Jul 20, 2022, ZEO ScientifiX has disclosed funding of $4.5M (USD). Undisclosed round amounts are excluded.
ZEO ScientifiX has 22 employees as of Feb 6, 2024.
